Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5)
- Target
- MAP4K5
- Molecular classification
- Enzyme, Serine/threonine protein kinase, Mitogen-activated protein kinase family
01
Overview
Mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5) is a cytoplasmic serine/threonine kinase and member of the MAPK signaling cascade, particularly upstream of JNK activation involved in cellular stress responses. It acts by transferring phosphate groups to specific substrate proteins and has homologs among yeast kinases functioning at the initiation of MAP kinase pathways. MAP4K5 participates in the regulation of immune responses, cell differentiation, and may have roles in disease states such as cancer and metabolic disorders. Its expression is cytoplasmic and tissue-specific, especially in smooth muscle and lymphoid organs, but its full physiological and pathological roles remain under investigation.
- Other names
- MAP4K5GCKRKHSKHS1MAPKKKK5Kinase homologous to SPS1/STE20Germinal center kinase-related
02
Mechanism of action
Drugs hypothetically targeting MAP4K5 would likely act as kinase inhibitors, blocking its phosphorylation activity and downstream activation of the JNK pathway.
03
Biological functions
Signal transductionStress responseActivation of Jun N-terminal kinase (JNK)Regulation of immune cell signaling and development (e.g., B and T lymphocytes)Possible role in Wnt-induced Rac-JNK signaling
04
Disease associations
Cancer (e.g., acute myeloid leukemia)Autoimmune inflammationObesityType 2 diabetes
05
Safety considerations
Inhibition may dysregulate immune function, stress responses, and potentially disrupt normal cell cycle and differentiation, warranting caution in therapeutic development for autoimmune, metabolic, or oncological indications.
06
Interacting drugs
No approved or investigational drugs directly targeting MAP4K5 are listed in major databases as of now. Some ligands and molecules used in screening may exist, as indicated by structure-activity data in pharmacology resources, but no clinical drug is specified.
07
Biomarkers
No validated biomarkers for patient selection or efficacy monitoring specific to MAP4K5 status are reported as of current knowledge.
Beyond the preview
Go deeper on Mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5).